A study, published recently in Clinical Lymphoma, Myeloma and Leukemia, has further validated the use of the SKY92 gene expression signature as a potentially valuable prognostic tool to evaluate myeloma patients. Compared with seven other gene expression profiling classifiers including UAMS 70, UAMS 80 and IFM15, the researchers found that SKY92 identified the largest proportion (21%) of high-risk patients, attained the highest Cox proportional hazard ratio for overall survival and predictive death rate. In addition, when combined with the International Staging System, SKY92 robustly identified low-risk myeloma patients. They concluded that these validated markers could not only stratify myeloma patients with high accuracy but also serve as the basis for the discovery of improved tailored treatments for the different groups of patients.